Clovis, Avila to Co-develop Targeted NSCLC Drug with Companion Test in Deal Worth up to $209M
May 26, 2010
Clovis, Avila to Co-develop Targeted NSCLC Drug with Companion Test in Deal Worth up to $209M
The companies are developing an EGFR mutant-selective inhibitor with a companion diagnostic that will select NSCLC patients with an EGFR mutation linked to resistance to drugs like Iressa and Tarceva.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Roche Receives FDA Nod for New PGx Indication for Tarceva in Metastatic NSCLC with Companion Dx
May 15, 2013 / Pharmacogenomics Reporter - Largest Trial of EGFR-Mutated NSCLC Patients Promises New Personalized Treatment Option
June 6, 2012 / Pharmacogenomics Reporter - Pfizer Using Qiagen KRAS Test to Study Dacomitinib Head-to-Head Against Tarceva in NSCLC
August 17, 2011 / Pharmacogenomics Reporter - Drugmakers' Commitment to Personalized Rx Growing Despite Barriers, PhRMA CEO Says
June 15, 2011 / Pharmacogenomics Reporter - Yale Researcher Suggests More Focus on EGFR Isoforms Needed in Development of Antibody-Based Drugs
May 20, 2011 / ProteoMonitor